Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Recalls Neutrogena Light Therapy Acne Mask On Reports Of Eye Injuries

Executive Summary

According to the J&J brand, a small subset of users with underlying eye conditions are potentially at risk of being injured by the FDA-cleared device, which uses red and blue LEDs to combat bacteria and inflammation associated with acne.

You may also be interested in...



J&J’s Aveeno Hair-Care Relaunch Per Vogue Model Helps Drive Consumer Q2 Improvements

Company leadership has said that Vogue International – the maker of OGX and Maui Moisture hair care that J&J acquired in 2016 – would serve as a model for innovations across other brands. Strategy appears to be paying off, contributing to gains in J&J's Consumer division, which also benefited in the second quarter from Zyrtec allergy treatment and children’s Tylenol and Motrin.

NAD: Firm's Laser Cap Hair-Regrowth Claims Not Supported, Despite FDA Clearance

The Capillus82 Hair Regrowth Laser Cap may be "substantially equivalent" to the manufacturer's Capillus272 Pro device, based on FDA's 510(k) clearance, but NAD says hair-growth clinical findings from that "predicate" device cannot serve to substantiate claims for the untested Capillus82. The case illustrates complexities in the medical device segment, which increasingly is of interest to cosmetics companies.

J&J Banking On Beauty Devices, 'Rapid' Anti-Aging For Consumer Growth

During an investor day conference held May 18, Johnson & Johnson execs discussed the firm's consumer business at length, offering a preview of dynamic new launches planned for the year.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel